Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies

Leukemia volume 19, pages 1267–1269 (2005)Cite this article

A Corrigendum to this article was published on 25 October 2005

TO THE EDITOR

A new SRC-Abl dual inhibitor, BMS354825, has recently been presented as a possible tool to overcome resistance to imatinib in neoplasias caused by oncogenic variants of the tyrosine kinase domain of Bcr-Abl.1 BMS354825 is able to inhibit in vitro and in vivo 14 of 15 imatinib-resistant Bcr-Abl mutants, while the T315I was clearly resistant to the compound.1 It has been suggested that BMS354825 could fit into a conformation of Abl different from the inactive one (ie the one that imatinib preferentially binds).1

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401.

    Article  CAS  Google Scholar 

  2. Rarey M, Kramer B, Lengauer T, Klebe G . A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996; 261: 470–489.

    Article  CAS  Google Scholar 

  3. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236–4243.

    CAS  PubMed  Google Scholar 

  4. Hubbard SR . Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 1997; 16: 5572–5581.

    Article  CAS  Google Scholar 

  5. Yamaguchi H, Hendrickson WA . Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 1996; 384: 484–489.

    Article  CAS  Google Scholar 

  6. Atwell S, Adams JM, Badger J, Buchanan MD, Feil IK, Froning KJ et al. A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase. J Biol Chem 2004; 279: 55827–55832.

    Article  CAS  Google Scholar 

  7. Corbin AS, Buchdunger E, Pascal F, Druker BJ . Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 2002; 277: 32214–32219.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by AIRC, FIRC, Min. San. Ricerca Finalizzata (2001, 2003), CNR, MIUR-COFIN and PRIN programs (2003,2004), EU (Prokinase network, Grant LSHB-CT-2004-503467), CIHR, NCI-C, CFI; originally submitted October 8, 2004.

Author information

Authors and Affiliations

  1. University of Milano Bicocca and National Cancer Institute, Milan, Italy

    C Gambacorti-Passerini

  2. Department of Oncology, McGill University, Montreal, Canada

    C Gambacorti-Passerini & S Assouline

  3. Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology (ETH), Zurich, Switzerland

    M Gasser

  4. Laboratoire de Chimie Thérapeutique, School of Pharmaceutical Sciences, Geneva University, Genève, Switzerland

    M Gasser, S Ahmed & L Scapozza

Authors
  1. C Gambacorti-Passerini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Gasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Ahmed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Assouline
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Scapozza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Scapozza.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gambacorti-Passerini, C., Gasser, M., Ahmed, S. et al. Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia 19, 1267–1269 (2005). https://doi.org/10.1038/sj.leu.2403775

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403775

This article is cited by

Search

Advanced search

Quick links